Membership, Supporting Dues, and Contributions

The iSAEC is a 501 c3 non-profit membership corporation (under the Internal Revenue Service Code) formed to engender the required organization, processes, and resources required to identify and validate DNA-variants useful in predicting the risk of drug induced serious adverse events (SAEs).  As such, it functions with the explicit purpose of enhancing the “public good”.  Its members are organizations engaged principally in the business of discovering, developing and marketing pharmaceutical products, or charitable, governmental, or other non-profit organization with an interest in the field of medical science. 

Membership in the iSAEC is open to all dues-paying parties with a strong interest in the Consortium’s scientific agenda.  Membership is open to pharmaceutical, biotech, clinical research organizations, and other healthcare related companies interested in improving the safe use of pharmaceutical products through the application of state-of-the art molecular biology.  The Consortium has a uniform, fixed membership dues structure defined by its Phase One research plan.  Inquires for the current iSAEC dues policies should be directed to Arthur Holden, Chairman on the SAEC.  Membership dues are deemed to be fully tax-deductible under the IRS code.

Membership in the iSAEC provides for a voting seat on the Consortium’s Board of Directors, and representation on the various working committees (see SAEC Organization).

Collaborators, government, and regulatory bodies can join as “associated members”.  Details of this membership can be obtained by directly contacting the Chairman of the iSAEC.

The Consortium will accept chartable contributions from individuals, foundations and other organizations interested in further the mission and work of the Consortium.  Inquires for such giving should be directed to Arthur Holden , Chairman on the iSAEC.

The iSAEC’s full “dues paying members” include the following organizations who have supported the Consortium’s research endeavors in Phase 1 and/or Phase 2:

In phase two, we also have two "in-kind" members supporting our efforts to identify and enroll SAE cases via electronic medical records datbases.  These in kind members include: